Original Article
Safety and efficacy of topical Crisaborole 2% ointment in the treatment of psoriasis on face, intertriginous and anogenital areas: A vehicle-controlled cross-over study
Author Details
1. Professor, Dept. of Dermatology and Associate Professor, Dept. of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.
2. Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.
3. National Heart Foundation, Dhaka, Bangladesh.
4. Consultant, Dept. of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.
5. Consultant, Dept. of Dermatology and Venereology, Shaheed Suhrawardy Medical College (ShSMC), Dhaka, Bangladesh.
6. Consultant, Central skin and social health care, Agrabad, Chittagong, Bangladesh.
7. Professor, Dept. of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.
Abstract Background: Psoriasis in some sensitive areas like the face, anogenital and intertriginous areas significantly affects patients' quality of life, and psycho-social and sexual well-being. Due to the special structural and functional characteristics of these areas, all sorts of topical agents are not suitable for use on lesions in these areas. Objective: To study the safety and efficacy of crisaborole 2% ointment in treating psoriasis on the face, anogenital and intertriginous areas. Methods: It was a randomized vehicle-controlled cross-over study. Thirty-two patients with psoriatic lesions on the face, anogenital and intertriginous areas were enrolled purposively. Selected single lesion was treated with vehicle ointment twice daily for 4 weeks followed by 2 weeks washout period. Then each lesion was again treated with 2% crisaborole ointment twice daily for 4 weeks. Psoriasis disease severity will be measured by the Target Lesion Severity Scale (TLSS) at weeks 0, and 4 during both treatment periods. Changes in TLSS scores were compared between the two groups. Result: Topical 2% crisaborole is effective in the treatment of psoriatic plaques as the mean reduction of TLSS score of each treated lesion of the patients was significant after 4 weeks of application compared with baseline and it is significantly better (p<0.001) than vehicle (p=0.257. Few adverse effects were noted including burning, itching and redness. Conclusion: Topical 2% crisaborole ointment is a safe and effective non-steroidal option for treating psoriasis lesions on the face, anogenital and intertriginous areas though for complete lesional clearance a longer treatment period may be needed. Keywords: Crisaborole, PDE-4 inhibitor, anogenital psoriasis, intertriginous psoriasis, facial psoriasis |
Keywords: Crisaborole, Pde-4 Inhibitor, Anogenital Psoriasis, Intertriginous Psoriasis, Facial Psoriasis